An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Inclusion Criteria:

1. Males and Females, age ≥ 18 years old
2. Newly diagnosed brain cancer or tumor called glioblastoma or GBM
3. Karnofsky performance status of ≥ 70 (able to take care of self)
4. Substantial recovery from surgery resection
5. Tumor test result shows MGMT methylated or indeterminate tumor subtype

Exclusion Criteria:

1. Biopsy-only of GBM with less than 20% of tumor removed
2. Prior treatment for GBM (other than surgical resection)
3. Any known tumor outside of the brain
4. Recurrent or secondary GBM
5. Active known or suspected autoimmune disease

Other protocol defined inclusion/exclusion criteria could apply